Evidence map›Paper›PMID 33790981›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Impact of Buzhong Yiqi Prescription on the Gut Microbiota of Patients with Obesity Manifesting Polycystic Ovarian Syndrome.

Zhexin Ni, Wen Cheng, Jie Ding, Ruipin Yao, Danying Zhang, Dongxia Zhai, Ling Zhou, Chaoqin Yu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Identification of the gut microbiota affectingFrontiers in microbiology · 2023
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhexin NiDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0002-9723-2398
Wen ChengDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0001-7006-4999
Jie DingDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-2701-9636
Ruipin YaoDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-4055-1053
Danying ZhangDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-3881-5195
Dongxia ZhaiDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0002-9053-4537
Ling ZhouDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-1600-4244
Chaoqin YuDepartment of Traditional Chinese Gynecology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-1614-2655
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota disorders are closely related to polycystic ovarian syndrome (PCOS). Buzhong Yiqi prescription (BZYQ) has a significant clinical effect on the treatment of patients with obesity exhibiting PCOS and phlegm-dampness syndrome caused by spleen deficiency (SPSD). Hence, this study aimed to explore gut microbiota and fecal metabolite alterations in such patients treated with BZYQ. Fifty eligible patients with obesity manifesting PCOS and SPSD participated and agreed to undergo 3 months of BZYQ treatment. Results showed that BZYQ significantly alleviated the serum dehydroepiandrosterone sulfate (

Identifiers

PMID33790981
PMCPMC7984899
OpenAlexW3139380309

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.